This way, the exploration of TLR agonists and antagonists as therapeutic modalities demonstrates the potential for drawing on immune responses against cancer cells, showing as a promising field of experimentation where more attention is expected, mainly due to the use of purine nucleoside phosphorylase inhibitors with immunotherapies that can enhance antitumor response. The gene discussed is PNP; the disease is cancer.